Status:
COMPLETED
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Solid Tumors
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
Eligibility Criteria
Inclusion
- Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
- Relatively good overall health other than cancer
Exclusion
- Poor bone marrow function (not producing enough blood cells)
- Poor liver or kidney function
- Serious concomitant illness
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00973076
Start Date
August 1 2009
End Date
December 1 2010
Last Update
June 15 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Tokyo, Japan